Caitlin Kontulis - 01 Mar 2024 Form 4 Insider Report for Phio Pharmaceuticals Corp. (PHIO)

Reporting relationship: Secretary & VP Finance & Admin
Issuer ticker: PHIO
Reported as of: 01 Mar 2024
Net transaction value: -$321
SEC form: 4
Accepted by SEC: 05 Mar 2024, 19:00:05 UTC
Prior SEC filing: 20 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Caitlin Kontulis

Key filing fact

Caitlin Kontulis filed Form 4 for Phio Pharmaceuticals Corp. (PHIO) on 05 Mar 2024.

Key facts

This page summarizes Caitlin Kontulis's Form 4 filing for Phio Pharmaceuticals Corp. (PHIO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Mar 2024, 19:00.

Change

Previous filing in this sequence was filed on 20 Feb 2024.
Current net transaction value: -$321.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PHIO transaction

Common stock, $0.0001 par value

Tax liability

Transaction value: $321
Shares: -335
Change %: -3.1%
Price: $0.9580
Shares after: 10,643
Date: 01 Mar 2024
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting of restricted stock units. No shares were sold.

Footnote F2

Includes shares of common stock underlying unvested restricted stock units.